Sanara MedTech Inc. Common Stock (SMTI) Stock Price
SMTIStock
$33.16+13.17%52W
Market Cap$304.68M
P/E—
PEG Ratio—
Div yield—
Beta1.20
SMTI Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)69.24%
Price vs S&P 500 (4W)-4.39%
VGM Score55.32
SMTI Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.07 | $0.09 | +223.14%(+$0.16) | |
| Q1 2026 | -$0.22 | $0.04 | +118.18%(+$0.26) | |
| Q4 2025 | $0.11 | -$0.19 | -272.73%(-$0.30) | |
| Q3 2025 | -$0.21 | -$3.52 | -1537.21%(-$3.31) | |
| Q2 2025 | -$0.44 | -$0.23 | +47.73%(+$0.21) |
SMTI Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.13
4.11
3.89
2.38
Industry Peers — Orthopedic & Prosthetic Devices(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
SMTISanara MedTech Inc. Common Stock | D | C | B | 2.8x | 45.9% | 93.0% | 7.7% | $33.16 |
| ISRGIntuitive Surgical Inc. | D | B | B | 13.7x | 18.2% | 66.7% | 31.3% | $426.70 |
| EWEdwards Lifesciences Corp | D | C | B | 7.7x | 6.7% | 77.8% | 18.2% | $86.60 |
| STESTERIS plc | C | C | B | 3.6x | 13.8% | 44.4% | 18.9% | $222.66 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | B | 2.1x | 3.2% | 69.9% | 14.2% | $94.98 |
| SNNSmith & Nephew plc | B | C | C | 1.9x | 6.2% | 68.2% | 12.9% | $29.06 |
| ALGNAlign Technology Inc | B | D | C | 2.5x | 10.3% | 69.0% | 13.2% | $147.31 |
| MSAMine Safety Incorporated | C | C | B | 3.5x | 6.8% | 47.6% | 21.2% | $179.05 |
| ESTAEstablishment Labs Holdings Inc. | F | A | C | 7.2x | 20.0% | 70.5% | -7.6% | $59.18 |
| ENOVEnovis Corporation | B | D | C | 0.5x | -6.0% | 61.4% | -45.1% | $19.59 |
| CDRECadre Holdings, Inc. | B | C | C | 1.6x | 8.6% | 41.8% | 10.1% | $26.38 |
About Sanara MedTech Inc. Common Stock
Sanara MedTech develops medical technologies for wound and skincare management across acute and post-acute care settings. Its portfolio includes CellerateRX for surgical wounds and BIAKOS for chronic wound care, addressing a substantial market opportunity. The company's comprehensive product offerings target improved clinical outcomes and reduced healthcare costs.